Exosome Diagnostics this week announced that it has signed a deal to collaborate with Eli Lilly on mRNA and microRNA biomarker discovery and validation.
Under the arrangement, Lilly will have early access to Exosome's EXO50 nucleic acid extraction kit, which isolates both mRNA and microRNA, and can distinguish between exosomal microRNA and protein-complexed microRNA. It will use the technology to identify gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.
Financial terms of the arrangement were not disclosed.